1150617-92-7Relevant articles and documents
Constrained formation of 2-(1-(arylimino)ethyl)-7-arylimino-6,6-dimethylcyclopentapyridines and their cobalt(ii) chloride complexes: Synthesis, characterization and ethylene polymerization
Ba, Junjun,Du, Shizhen,Yue, Erlin,Hu, Xinquan,Flisak, Zygmunt,Sun, Wen-Hua
, p. 32720 - 32729 (2015)
A series of 2-(1-(arylimino)ethyl)-7-arylimino-6,6-dimethylcyclopentapyridine derivatives (L1-L5) was synthesized, and individually reacted with cobalt(ii) chloride to form the corresponding cobalt chloride complexes (C1-C4). These compounds were characte
AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
-
, (2016/06/21)
Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein "R1", "RA-1", "R2", "R3", and "Het" are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
AMIDE COMPOUND
-
Page/Page column 70-71, (2011/04/18)
The present invention aims to provide a prophylactic or therapeutic agent for schizophrenia and the like, containing the compound of the present invention having a GPR52 agonist activity. A compound represented by the following formula (I) or a salt there